HLS Therapeutics Inc (HLS : TSX)
Common Stock
$4.47
CAD
+0.13 (3.00%)
Last updated: 2026-06-22
HLS
HLS Therapeutics Inc
WealthAwesomePerformance
1 Day
+3.00%
1 Week
+3.95%
1 Month
-3.66%
YTD
-7.84%
Key Statistics
Market Cap
$135.73M
52W High
$5.76
52W Low
$4.11
P/E Ratio
-
50 Day MA
$4.55
200 Day MA
$4.84
Beta
0.85
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 6/22/2026 | $4.46 | $4.56 | $4.44 | $4.47 | $4.47 | 10,619 |
| 6/19/2026 | $4.25 | $4.42 | $4.21 | $4.34 | $4.34 | 2,500 |
| 6/18/2026 | $5.04 | $5.04 | $4.12 | $4.29 | $4.29 | 25,806 |
| 6/17/2026 | $4.40 | $4.44 | $4.35 | $4.39 | $4.39 | 11,094 |
| 6/16/2026 | $5.25 | $5.25 | $4.24 | $4.39 | $4.39 | 50,716 |
| 6/15/2026 | $4.35 | $4.37 | $4.11 | $4.30 | $4.30 | 34,823 |
| 6/12/2026 | $4.35 | $4.36 | $4.28 | $4.36 | $4.36 | 6,627 |
| 6/11/2026 | $4.35 | $4.45 | $4.32 | $4.45 | $4.45 | 27,407 |
| 6/10/2026 | $4.35 | $4.41 | $4.34 | $4.35 | $4.35 | 5,160 |
| 6/9/2026 | $4.35 | $4.35 | $4.35 | $4.35 | $4.35 | 210 |
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 64.3% over the next 12 months.
Consensus
No RatingAvg. Target
C$7.34
+64.3% Upside
Current Price
C$4.47
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
23.5%
Annualized
90-Day Vol
18.2%
Annualized
Trend (90d)
+8.5%
Annualized drift
90d Mean
C$4.61
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$4.52 | C$4.16 โ C$4.90 |
| 60 trading days | C$4.56 | C$4.07 โ C$5.12 |
| 90 trading days | C$4.61 | C$4.01 โ C$5.30 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About HLS Therapeutics Inc
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril; Nilemdo, a bempedoic acid product for cardiovascular risk reduction; Nexlizet, a bempedoic acid and ezetimibe product for cardiovascular risk reduction; and Vascepa, an icosapent ethyl capsule for the treatment of cardiovascular disease. It also distributes MyCare psychiatry lab assays, which are a line of tests that can be processed on analyzers used in laboratory systems to measure the blood levels of the most common antipsychotic drugs, including clozapine, risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone; and MyCare Insite, a point-of-care device that requires only a single drop of blood taken by a finger stick to measure patient drug levels. In addition, the company holds royalty interest in Takeda's Obizur, a porcine recombinant Factor VIII for acquired Hemophilia A. It serves wholesalers and institutions. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
Financials
- Revenue (TTM)
- $55.74M
- EBITDA
- $17.34M
- Profit Margin
- -18.46%
- ROE (TTM)
- -16.42%
- EPS (Diluted)
- -0.45
- Book Value
- 2.45
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About HLS
Articles Featuring HLS.TO
Latest articles and analysis covering HLS.TO
Why HLS Therapeutics Inc stock is skyrocketing today
HLS Therapeutics Inc has experienced a significant 7.38% increase in stock price, driven by positive financial results and strategic product launches, positioning the company for potential growth in the competitive pharmaceutical market.
Why HLS Therapeutics Inc stock is gaining today
HLS Therapeutics Inc has gained 1.17% in its stock price today, fueled by encouraging sales figures for its flagship product, Vascepa.
Why HLS Therapeutics Inc stock is sliding today
HLS Therapeutics Inc (HLS.TO) has seen a significant decline in its stock price, closing down 4.33% at CA$4.20. Despite reporting growth in revenue and reaffirming financial guidance, investor sentiment appears to be wavering.
Why HLS Therapeutics Inc stock is tanking today
HLS Therapeutics Inc's stock is struggling today, down 0.91%, as investors weigh the implications of its recent financial results amidst broader market concerns.
Why HLS Therapeutics Inc stock is rising today
HLS Therapeutics Inc's stock price rose by 2.33% in the last trading session, closing at CA$4.40. This increase follows a series of positive financial results, including a significant rise in revenue and cash flow, hinting at a potentially strong future for the company.
Why HLS Therapeutics Inc stock is sliding today
HLS Therapeutics Inc's stock slid 3.15% today, closing at CA$4.31, as investors react to mixed financial signals and a challenging market environment.
